KQ-2003 CAR T-cells

BIOLOGICAL2 trials

Sponsors

Novatim Immune Therapeutics (Zhejiang) Co., Ltd.

Conditions

Multiple MyelomaPOEMS Syndrome

Phase 1

A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory Multiple Myeloma

RecruitingNCT06223646

Novatim Immune Therapeutics (Zhejiang) Co., Ltd.Multiple Myeloma

Start: 2024-01-11End: 2026-03-31Target: 29Updated: 2024-01-25

A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory POEMS Syndrome

Not yet recruitingNCT06518876

Novatim Immune Therapeutics (Zhejiang) Co., Ltd.POEMS Syndrome

Start: 2024-08-31End: 2027-12-31Target: 21Updated: 2024-07-24

Related Papers

Abstract CT253: First in India, phase 1/2 study of an indigenously adapted, cost-efficient autologous dual-target BCMA/CD19 CAR T-cell therapy for relapsed or refractory multiple myeloma

Cancer Research2026-04-17

A Prospective Investigator-Initiated Phase 1/2 Study of BCMA/CD19 Dual-Targeting CAR T Therapy in Patients with Relapsed/Refractory Multiple Myeloma Including Those with Extramedullary Disease

Blood2024-11-053 citations